Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Most people with multiple myeloma are diagnosed in their 60s, 70s or 80s. “Myeloma is predominantly a disease of aging, so the older you get, the more likely you are to get it,” Mohyuddin said.

Here’s my take on myeloma-related studies that I’m excited about now and in the year ahead, with a focus on smoldering multiple myeloma (SMM), newly diagnosed disease, and first relapse. A key ...

An analysis of IBM rates for multiple myeloma from 2000 to 2021 found that significant disparities persist in myeloma outcomes based on household income and geographic location. 1 Drawing on SEER ...

Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are “hideously expensive,” Dr. June said, costing more than $100,000 a year.

Meanwhile, Pfizer’s bispecific antibody for multiple myeloma is Elrexfio, which targets BCMA on cancer cells and CD38 on T cells. Elrexfio is administered every two weeks after step-up dosing.

We conducted a phase 1b–2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. In phase 1, we investigated five dose levels in a dose-escalation study.